SCHEMBL3399487

SCHEMBL3399487

CC(=O)c1ccc2c(c1)Cc1cc(C(C)=O)ccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 1.00
NPC1 O15118 2/20 1.00
MAPT P10636 1/20 1.00
HSD17B1 P14061 1/20 0.82
SRD5A2 P31213 1/20 0.56
PGR P06401 1/20 0.56
KCNH2 Q12809 1/20 0.51
HTR2C P28335 2/20 0.50
HTR2B P41595 2/20 0.50
CYP1A2 P05177 1/20 0.50
ADRA2A P08913 1/20 0.50
MAOA P21397 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
KCNJ1 P48048 1/20 0.49
KMT2A Q03164 1/20 0.49
S100A4 P26447 1/20 0.48
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
DRD2 P14416 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692090 1.00 RAB9A (1.00) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL11841857 0.94 MAPT (0.89) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL26575463 0.92 MAPT (0.85) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL407340 0.91 MAPT (0.82) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL4945231 0.91 HSD17B1 (1.00) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL26575457 0.91 RAB9A (0.82) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL26185760 0.89 RAB9A (0.79) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL5048102 0.89 RAB9A (0.79) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL11839424 0.89 RAB9A (0.79) RAB9ANPC1MAPTHSD17B1SRD5A2
SCHEMBL15202656 0.89 MAPT (0.80) RAB9ANPC1MAPTHSD17B1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117264181-A Preparation method and application of PTSA (Positive temperature coefficient) catalyzed green porous organic polymer under solvent-free condition 潍坊医学院附属医院 2023-12-22 CN claimed
CN-104603215-A Composition for coating high refractive layer and transparent conductive film comprising same LG HAUSYS LTD 2015-05-06 CN claimed
CN-117264181-B Preparation method and application of PTSA (Positive temperature coefficient) catalyzed green porous organic polymer under solvent-free condition 潍坊医学院附属医院 2024-01-26 CN disclosed
CN-117264181-A Preparation method and application of PTSA (Positive temperature coefficient) catalyzed green porous organic polymer under solvent-free condition 潍坊医学院附属医院 2023-12-22 CN disclosed
US-20230330045-A1 THE ANTIVIRAL DRUG TILORONE IS A POTENT AND SELECTIVE INHIBITOR OF ACETYLCHOLINESTERASE COLLABORATIONS PHARMACEUTICALS, INC. 2023-10-19 US disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 EP disclosed
EP-2802326-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-18 EP disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-20160199355-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MAYERS SQUIBB COMPANY (US) 2016-07-14 US disclosed
US-20160158200-A1 Combinations of Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-06-09 US disclosed
US-9326973-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-03 US disclosed
EP-0666267-B1 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM CO (US) 2001-04-18 EP disclosed
WO-2001019792-A1 COVALENTLY LINKED DIMERIC DNA BINDING MOLECULES GENELABS TECHNOLOGIES, INC. (US) 2001-03-22 WO disclosed
CN-1060176-C Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM CO (US) 2001-01-03 CN disclosed
US-5668230-A METALLOCENE WITH ETHYLENE BRIDGED FLUORENE UNITS, ALUMOXANE COCATALYST PHILLIPS PETROLEUM COMPANY (US) 1997-09-16 US disclosed
US-5571880-A CATALYSTS FOR POLYMERIZATION OF OLEFINS ESPECIALLY TO OBTAIN SYNDIOTACTIC POLYMERS PHILLIPS PETROLEUM COMPANY (US) 1996-11-05 US disclosed
CN-1109472-A Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM CO (US) 1995-10-04 CN disclosed
EP-0666267-A2 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM COMPANY (US) 1995-08-09 EP disclosed
US-4064347-A Bis-basic ketones of fluorene and fluorenone RICHARDSON-MERRELL INC. (US) 1977-12-20 US disclosed
US-3939276-A ANTHRAQUINONES, ASTHMA, ANTIALLERGENS BURROUGHS WELLCOME CO. (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160199355-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, MAVS, EIF2AK2 RAB9A 1490/4885NPC1 414/4885MAPT 3132/4885
US-20160158200-A1 Combinations of Hepatitis C Virus Inhibitors HAVCR2, EIF2AK2, MAVS RAB9A 1807/4885NPC1 706/4885MAPT 3548/4885
US-20230330045-A1 THE ANTIVIRAL DRUG TILORONE IS A POTENT AND SELECTIVE INHIBITOR OF ACETYLCHOLINESTERASE ACHE, BCHE, ACE RAB9A 2916/4885NPC1 3609/4885MAPT 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.